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ABSTRACT
Subclonal heterogeneity and clonal selection influences disease progression 
in chronic lymphocytic leukemia (CLL). It is therefore important that therapeutic 
decisions are made based on an understanding of the CLL clonal architecture and its 
dynamics in individual patients. Identification of cytogenetic abnormalities by FISH 
remains the cornerstone of contemporary clinical practice and provides a simple 
means for prognostic stratification. Here, we demonstrate that multiplexed-FISH can 
enhance recognition of CLL subclonal repertoire and its dynamics during disease 
progression, both in patients and CLL patient-derived xenografts (PDX). We applied 
a combination of patient-specific FISH probes to 24 CLL cases before treatment and 
at relapse, and determined putative ancestral relationships between subpopulations 
with different cytogenetic features. We subsequently established 7 CLL PDX models 
in NOD/Shi-SCID/IL-2Rγctm1sug/Jic (NOG) mice. Application of multiplexed-FISH to 
these models demonstrated that all of the identified cytogenetic subpopulations 
had leukemia propagating activity and that changes in their representation during 
disease progression could be spontaneous, accelerated by treatment or treatment-
induced. We conclude that multiplexed-FISH in combination with PDX models have the 
potential to distinguish between spontaneous and treatment-induced clonal selection, 
and therefore provide a valuable tool for the pre-clinical evaluation of novel therapies.
INTRODUCTION
Genomic aberrations play an important pathogenic 
role in chronic lymphocytic leukemia (CLL), by shaping 
its clinical course and response to treatment [1]. It was 
recognized as early as the 1990s that certain cytogenetic 
aberrations confer differential clinical outcomes, 
culminating in the hierarchical classification scheme 
devised by Döhner and colleagues that continues to 
be of major clinical relevance to this day [2]. In recent 
years, next generation sequencing (NGS) has allowed 
identification of recurrent genetic mutations, providing 
an additional dimension to the CLL genomic landscape 
[3–8]. However, despite the informative potential of NGS 
technology, identification of cytogenetic abnormalities by 
FISH remains the cornerstone of contemporary clinical 
practice, and continues to provide a validated, simple and 
cost-effective means of stratifying patients into distinctive 
prognostic subgroups who could benefit from different 
therapeutic approaches.
Among the most frequent cytogenetic lesions in 
CLL, del(17p) is associated with the worst prognosis, 
followed by del(11q). Trisomy 12 and del(6q) confer 
intermediate risk, while patients with normal karyotype or 
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isolated del(13q) have the most favorable outcome [9–12]. 
Del(17p) and del(11q) are enriched in patients relapsing 
from chemotherapy or chemoimmunotherapy, which 
may reflect chemotherapy-driven selection of aggressive 
subclones containing these cytogenetic aberrations [12–
17]. Equally, cytogenetic abnormalities are clinically 
significant in the context of targeted therapies such as the 
B-cell receptor (BCR) signaling inhibitor ibrutinib, with 
the majority of relapsing cases featuring del(17p), del(11q) 
and/or complex metaphase cytogenetics [18, 19].
Given the clinical importance of cytogenetics in 
CLL, it is relevant to ask how cytogenetic aberrations 
evolve, either spontaneously or under different treatments. 
Multiplexed-FISH, which involves the simultaneous 
use of multiple FISH probes corresponding to different 
chromosomal regions of interest, permits resolution of 
subclonal complexity and assessment of the cytogenetic 
composition at the single-cell level [20]. Longitudinal 
tracking of cytogenetic abnormalities by multiplexed-FISH 
may therefore provide potentially valuable information on 
their evolutionary pattern in individual patients under the 
influence of different treatments. This is not possible with 
comparative genome hybridization or single-nucleotide 
polymorphism array-based methodologies that are carried 
out on bulk cellular populations [21, 22].
Importantly, the application of multiplexed-FISH 
in CLL patient-derived xenograft (PDX) models has the 
potential to enhance their utility as tools for pre-clinical 
drug evaluation. Anderson and colleagues demonstrated 
the use of multiplexed-FISH to interrogate subclonality 
not only in samples from patients with acute lymphoblastic 
leukemia (ALL) but also in ALL PDX, allowing delineation 
of the composition of cytogenetic abnormalities in leukemia 
propagating cells [20]. Given the relatively limited number 
of recurrent cytogenetic abnormalities in CLL, we reasoned 
that multiplexed-FISH would be ideally suited to investigate 
whether distinct CLL subpopulations containing different 
combinations of cytogenetic aberrations can be recapitulated 
in PDX models as observed in acute leukemias. Moreover, 
we reasoned that modeling cytogenetic aberrations in 
PDXs would enable assessment of the impact of different 
treatments on the clonal cytogenetic architecture. In light of 
the multitude of novel therapeutic agents currently under 
investigation for CLL and the trend towards precision 
medicine, in vivo modeling of clonal selection and dynamics 
in PDXs could be invaluable in informing therapeutic 
stratification.
In this study, we demonstrate the functional utility 
of multiplexed-FISH in CLL. The combinations of 
cytogenetic aberrations in 24 untreated CLL samples 
were established at single-cell resolution by multiplexed-
FISH from which putative ancestral relationships between 
CLL subpopulations with different cytogenetic features 
were established. In selected cases, we also analyzed 
sequential samples to assess the impact of treatment upon 
the composition of cytogenetic aberrations at the single-
cell level. In addition, multiplexed-FISH analysis of 
PDX models was employed to interrogate the leukemia 
propagating activity of distinct CLL subpopulations carrying 
different combinations of cytogenetic lesions. Finally, and 
most importantly, we demonstrated that changes in the CLL 
cytogenetic architecture, both spontaneous and treatment-
induced, can be modeled in PDXs.
RESULTS
Multiplexed-FISH provides a single-cell 
resolution snapshot of the CLL cytogenetic 
architecture
Initially, we screened untreated CLL samples from 
128 individuals for the presence of clinically relevant 
cytogenetic lesions, namely del(11q22.3), del(17p13.1), 
del(13q14.3), del(6q23.3) and trisomy 12, and identified 
a cohort of 24 patients with at least two cytogenetic 
abnormalities (Figure 1A). This cohort was enriched for 
the presence of del(11q) and del(17p), two cytogenetic 
abnormalities that are frequently associated with a 
complex karyotype.
We then performed multiplexed-FISH using 
combinations of FISH probes specific for each patient 
and based upon the cytogenetic aberrations detected in the 
initial round of single probe FISH (Supplementary Table 
2). Two hundred cells were assessed for the simultaneous 
presence of patient specific probes, and the different 
combinations recorded. The cohort analyzed revealed 
varied genetic heterogeneity in relation to these markers, 
with samples displaying 3 to 8 distinct cytogenetic 
combinations (Figure 1B). Thus, our results demonstrate 
the ability of multiplexed-FISH to detect multiple 
CLL subpopulations containing distinct combinations 
of clinically relevant cytogenetic lesions, providing a 
snapshot of the cytogenetic architecture at single-cell 
resolution.
Multiplexed-FISH reveals distinct evolutionary 
patterns of cytogenetic aberrations under 
different treatments
As multiplexed-FISH enables identification of 
multiple cytogenetic lesions in single cells, we used 
this information to infer the temporal order of the 
acquisition of cytogenetic lesions and to decipher the 
likely evolutionary patterns in each untreated CLL sample 
[20]. This analysis uncovered two possible evolutionary 
patterns. The majority of cases (20/24) were likely to have 
undergone branching clonal evolution where at least one 
subpopulation acquired genetic alterations giving rise to 
two or more distinct subpopulations. Four cases, however, 
accumulated the cytogenetic abnormalities probably 
in a stepwise manner consistent with linear evolution 
(Figure 2A). Samples displaying branching cytogenetic 
evolution could be further subdivided into those with 
simple subclonal branching (Figure 2B) and others with 
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Figure 2: Multiplexed-FISH resolves both branching and linear evolution in CLL. Multiplexed-FISH analysis enables 
establishment of the evolutionary history of a sample revealing that CLL populations undergo either (A) linear, (B) simple branching or 
(C) complex branching patterns of evolution. Original magnification ×100. Solid arrows denote the likely trajectory of evolution; dashed 
arrows denote possible trajectories. Numbers in brackets denote percentage of cells in that subclone. 6q- indicates del(6q); 11q-: del(11q); 
13q-: del(13q); 13q-/-: del(13q)x2. Probe combinations were (A, B) 13q: yellow; 11q: green; 17p: red; (C) 13q: yellow; 6q: aqua; 11q: red; 
CEP11 (chromosome 11 control): green.
Figure 1: Multiplexed-FISH reveals cytogenetic subclonal heterogeneity in CLL. (A) From 128 CLL patients, these 24 pre-
treatment CLL samples were identified as amenable for multiplexed-FISH based on the presence of del(6q), del(11q), del(13q), del(17p) and 
trisomy 12 in various combinations. (B) Multiplexed-FISH with patient-specific probe combinations revealed the cytogenetic architecture 
of each of the 24 CLLs. The size of each clone is expressed as a proportion of the total number (≥200) of cells analyzed. The samples are 
arranged according to the cytogenetic complexity, with those having fewer different subclones placed on the left side of the figure. The most 
complex subclones are presented at the top of each bar. +12 indicates trisomy 12.
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a more complex pattern characterized by the presence of 
multiple nodes (Figure 2C). CLL samples carrying both 
del(11q) and del(13q), the most common combination 
of cytogenetic abnormalities identified in our cohort 
(Figure 1A), exhibited both linear and branching patterns 
(Supplementary Table 2).
To determine changes in the composition of 
clinically relevant cytogenetic aberrations under the 
influence of different treatments, we analyzed 11 CLL 
cases by multiplexed-FISH in longitudinal samples 
taken before treatment and at relapse following either a 
single (n=8) or multiple (n=3) courses of chemotherapy, 
immunotherapy or chemoimmunotherapy (Table 1). We 
observed clonal stability in 4/11 cases with no change in 
the dominant subpopulation between pre-treatment and 
relapse (Figure 3A), and clonal selection in 7/11 cases 
where a minor subpopulation in the pre-treatment sample 
became dominant at relapse (Figure 3B). Of note, CLL2 
and CLL8 harbored small subpopulations containing 
del(17p) but displayed clonal stability in response 
to chemotherapy. Although their CLL subsequently 
progressed, significant selection of subpopulations with 
del(17p) was not evident at relapse, suggesting that 
there may be other genetic events responsible for disease 
progression in these patients (Figure 3A). Interestingly, 3/7 
cases with clonal selection also displayed clonal evolution, 
manifested by the emergence of CLL subpopulations 
carrying novel combinations of cytogenetic aberrations 
at relapse (Figure 3C). Given the limited number of cells 
assessed by multiplexed-FISH, it is plausible that these 
apparently novel subpopulations could have been present 
at very low frequencies in the pre-treatment sample and 
therefore evaded detection by multiplexed-FISH.
Collectively, our results revealed distinct 
evolutionary patterns of cytogenetic lesions at the single-
cell level. Different evolutionary patterns could be 
observed during disease progression in cases with initially 
similar cytogenetic composition.
Clonal cytogenetic repertoire in CLL patients is 
broadly recapitulated in PDX models
It has previously been shown from PDX of acute 
leukemias that all leukemic subclones identified in patients 
display a propensity to engraft and proliferate in mice [23–
27]. Conversely, the in vivo proliferative potential of CLL 
subpopulations with different genetic features is largely 
unknown. To investigate this, we generated PDXs using 
the pre-treatment sample from 7 CLL cases with multiple 
cytogenetic abnormalities. At 3-5 weeks following 
engraftment, FACS (fluorescence-activated cell sorting) 
sorted splenic CLL cells were analyzed by multiplexed-
FISH (Supplementary Figure 1).
All CLL subpopulations in the samples from our 
cohort, identified by multiplexed-FISH based on their 
unique cytogenetic features, were capable of engrafting 
Table 1: CLL patient treatment and subclonal responses at relapse
Tumor 1st Treatment Response 2nd Treatment Response Clonal Response
CLL2 Clb PR Flu NR Stable
CLL3 FC PR Campath PR Selection with evolution
CLL4 FC CR Ibrutinib PR Selection
CLL6 FC PR - - Stable
CLL8 Flu PR SCT CR Stable
CLL13 Clb PR Clb PR Selection
CLL14 Clb CR Clb NR Selection
CLL16 Flu PR SCT CR Selection with evolution
CLL18 Clb CR - - Selection with evolution
CLL19 FC CR Campath CR Stable
CLL32 FC PR FCR PR Selection
Paired pre-treatment and relapse samples of 11 patients were analyzed by multiplexed-FISH. Clonal response was 
determined by comparison of the subclonal architecture between pre-treatment and relapse samples. A ≥15% increase in a 
subclone size was considered indicative of clonal selection.
Note: Bold text indicates the treatment administered preceding the analysed relapse sample; Clb, chlorambucil; FC(R), 
fludarabine cyclophosphamide (rituximab); Flu, fludarabine; SCT, stem cell transplant; NR, no response; PR, partial 
response; CR, complete response.
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Figure 3: Multiplexed-FISH reveals differential subclonal responses to therapy in CLL. Analysis of paired patient pre-
treatment (P) and relapse (R) samples reveals different patterns of cytogenetic subclonal response. The observation time between each 
paired sample in months (mo) is shown. (A) Clonal stability with no change in the dominant clone between pre-treatment and relapse 
sample is observed in CLL2 and CLL8. (B) Clonal selection with a minor population in the pre-treatment sample becoming dominant 
at relapse is noted in CLL13 and CLL14. (C) Clonal evolution with the emergence of subpopulations carrying novel combinations of 
cytogenetic aberrations at relapse is evident in CLL3, CLL16 and CLL18. FC indicates fludarabine/cyclophosphamide; Clb: chlorambucil; 
Flu: fludarabine. Cytogenetic aberrations as denoted in Figures 1 & 2; 17p-: del(17p). Statistical significance denoted by ***P<0.001.
and proliferating in the PDX. However, in terms of 
subclonal similarity between patients and xenografts we 
observed two different trends.
Notwithstanding minor variability across animals, 
in the PDX established for CLL7, CLL13 and CLL31 
we observed that the clonal cytogenetic architecture in 
xenografts broadly resembled that of the pre-treatment 
CLL sample from which they were derived (Figure 4A).
In contrast, the cytogenetic architecture of CLL2, 
CLL14, CLL17 and CLL20 PDXs differed from the pre-
treatment sample, indicating spontaneous clonal selection 
in vivo. In the CLL17 PDX, the selected subpopulation 
was the most cytogenetically complex, with concurrent 
deletions in 6q, 11q and 13q, whereas in the CLL14 
PDX, two subpopulations, containing sole trisomy 12 
and del(11q)/trisomy 12, respectively, were selected. 
In the CLL20 PDX, two of the three xenografts (M2/
M3) displayed increased size of the del(11q)/del(13q) 
subpopulation, whereas the third xenograft (M1) displayed 
a four-fold increase in the biallelic del(13q) subpopulation 
(Figure 4B).
Importantly, in CLL14, the cytogenetic architecture 
of the PDX resembled that of the relapse sample (Figure 
4B). For CLL17 and CLL20, relapse samples were not 
available, and therefore it was not possible to determine 
whether the cytogenetic architecture in these xenografts 
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also resembled later stages of disease. In CLL2, there 
appears to be an expansion of the dominant subpopulation 
containing a sole del(13q) in 2/3 xenografts (M1/M3), 
such that the cytogenetic architecture was comparable to 
the relapse sample. However, unlike in CLL14, CLL17 
and CLL20, the clonal changes in CLL2 were not 
statistically significant. The accelerated clonal progression 
in PDXs from CLL2 and CLL14 resembled chlorambucil-
induced changes in the patients. Thus, it appears that in 
those cases post-treatment alterations may be spontaneous 
rather than treatment-driven, and possibly only accelerated 
by treatment. Of note, another PDX derived from a 
chlorambucil treated patient, CLL13, resembled the pre-
treatment sample rather than the relapse sample. However, 
this patient had a longer progression free survival (PFS; 
24.1 months) than CLL2 (9.2 months) and CLL14 (7.2 
months) suggesting that the rapidity of the clonal changes 
in the PDX might reflect the disease course.
Collectively, our findings suggest that CLL PDX 
models broadly recapitulate the clonal cytogenetic 
repertoire observed in patients. Consistent with previous 
reports regarding well-established PDX models of ALL, 
our results also show that, in certain instances, clonal 
changes may occur at an accelerated rate in the PDX 
relative to the patient [28]. Many factors may contribute to 
this phenomenon including the efficiency of cell handling, 
transfer, homing and the balance between cell death and 
proliferation. However, it also appears that PDX clonal 
dynamics reflects the disease course as clonal shift broadly 
correlated with patients’ PFS. Thus, clonal changes in 
untreated xenografts reflect spontaneous clonal selection/
evolution, and could provide a model for natural disease 
progression in individual patients.
Multiplexed-FISH combined with PDX enables 
modelling of spontaneous and treatment-
induced change in the CLL clonal cytogenetic 
architecture
Dynamic changes in the CLL clonal architecture 
can result from treatment-induced as well as spontaneous 
clonal progression. Having demonstrated that all CLL 
subpopulations detected by multiplexed-FISH can engraft 
in PDX models and that their dynamics can be captured, 
we next addressed the impact of different treatments 
on the clonal cytogenetic repertoire. We compared the 
cytogenetic evolutionary dynamics in response to DNA 
damaging agents (e.g. chlorambucil and fludarabine/
cyclophosphamide (FC), monoclonal antibodies (e.g. 
rituximab) and clinically relevant small molecule 
inhibitors such as ibrutinib. To prevent excessive tumor 
load reduction which could hinder the likelihood of 
capturing the full range of subpopulations, including 
those at low frequencies, we treated CLL PDX models 
with reduced intensity therapeutic schedules. Our results 
revealed three different patterns of clonal dynamics.
Figure 4: Recapitulation of patient cytogenetic profiles in CLL PDX models. Irradiated (1.25Gy) NOG mice were intravenously 
co-injected with 2-5x107 cells from a pre-treatment CLL sample and 1x105 stimulated autologous T-cells. Multiplexed-FISH was used to 
assess the cytogenetic architecture of the patients’ pre-treatment sample (P), patients’ relapse (R) and FACS sorted cells from CLL PDX’s 
(M) for seven tumors. This revealed that the subclonal cytogenetic composition of the input and engrafted cells could be either (A) highly 
similar (CLL7, CLL13, CLL31) or (B) significantly altered (CLL2, CLL14, CLL17, CLL20). M-1, M-2, M-3 and M-4 denote individual 
mice for each tumor (technical replicates). Cytogenetic aberrations are denoted as in Figures 1, 2 & 3. Statistical significance denoted by 
*P<0.05; ***P<0.005.
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In CLL20, both untreated and vehicle-treated 
xenografts showed a significant difference in cytogenetic 
architecture compared to the pre-treatment patient sample, 
with selection of the del(11q)/del(13q) subpopulation 
(P<0.05; Figures 4B & 5A). More substantial selection 
of the same subpopulation was observed when xenografts 
were treated with FC (Figure 5A and Supplementary 
Figure 2). This finding supports the notion that 
chemotherapy can accelerate spontaneous selection for 
subclones with DNA damage response gene alterations 
such as those carrying del(11q), the ATM gene site. This 
in turn results in an inferior response to chemotherapy [13, 
15].
On the contrary, in CLL17, all xenografts, whether 
vehicle-treated or rituximab-treated, displayed similar 
selection for the most complex subclone carrying all 
three abnormalities: del(6q), del(11q) and del(13q) 
(P<0.05; Figures 4B & 5B and Supplementary Figure 3). 
This is consistent with spontaneous clonal selection that 
occurred during xenotransplantation where no further 
substantive change in the cytogenetic architecture was 
observed upon treatment with monoclonal antibody. 
Whilst sub-optimal PDX treatments generally induced 
minimal tumor loss, rituximab caused a significant tumor 
reduction in PDX CLL17 suggesting that this aggressive 
and rapidly proliferating CLL was particularly susceptible 
to rituximab-mediated cytotoxicity.
Finally, a CLL13 PDX was established to compare 
the impact of two treatment modalities: chemotherapy and 
targeted therapy. The patient in this case was treated with 
chlorambucil and achieved a partial response. Subsequent 
relapse was characterized by differential outgrowth of 
the del(11q)/trisomy 12 subpopulation relative to the 
subpopulation carrying sole trisomy 12 (Supplementary 
Table 2 and Figures 4A & 5C). Chlorambucil-treated 
xenografts showed similar selection for the del(11q)/
trisomy 12 subpopulation with a concomitant reduction 
in the subpopulation with sole trisomy 12 (P<0.01) 
(Figure 5C and Supplementary Figure 4). In contrast, 
CLL13 xenografts treated with ibrutinib showed a trend 
towards selection for the cytogenetically more complex 
subpopulation carrying trisomy 12 in combination 
with del(6q) and del(11q). These changes were not 
observed in the vehicle-treated xenografts (Figure 5C 
and Supplementary Figure 5). Thus, this PDX model 
demonstrated treatment-specific changes in the clonal 
cytogenetic repertoire.
Taken together, our results suggest that multiplexed-
FISH in combination with CLL PDX models can 
potentially discriminate between the following types 
of changes in the clonal cytogenetic architecture: (a) 
spontaneous clonal progression that can be accelerated 
by treatment (e.g. CLL20 PDX); (b) spontaneous clonal 
progression that is unaffected by treatment (e.g. CLL17 
Figure 5: Effect of therapy on the cytogenetic architecture in CLL PDX models. Subsequent to evidence that established 
PDX models were generated from 3 CLLs; usually one to two weeks after CLL/T-cell co-injection; they were treated under different 
protocols. Mice were sacrificed one week after fludarabine/cyclophosphamide, rituximab or chlorambucil treatment, or the day following 
cessation of ibrutinib treatment. Splenic tumor load was assessed by FACS analysis (left side of each panel). The cytogenetic architecture 
was derived from sorted splenic CLL cells (right side of each panel). (A) CLL20 PDX was treated with fludarabine and cyclophosphamide 
(0.625mg/kg and 6.25mg/kg, respectively; FC; n=3) or saline (vehicle; V; n=3) three times per week for two weeks. (B) CLL17 PDX was 
treated with rituximab (40mg/kg; n=3) or saline (V; n=3) three times over the course of a week. (C) CLL13 PDX was treated either with 
chlorambucil (5mg/kg; n=4) versus 3% DMSO (V; n=3) daily for five days (left panel) or with ibrutinib (12.5mg/kg; n=3) versus 1% 
methylcellulose/0.4% Cremephor EL (V; n=4) for nine days (right panel). Cytogenetic aberrations are denoted as in Figures 1, 2 and 3. Data 
are represented as mean ± SEM. Statistical significance denoted by *P<0.05; **P<0.01.
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PDX); and (c) treatment-induced clonal progression (e.g. 
CLL13 PDX).
DISCUSSION
FISH remains the most widely used methodology 
for the evaluation of cytogenetic abnormalities in clinical 
practice despite the advent of targeted sequencing which 
is becoming more broadly available. The latter technique 
also requires substantial optimization regarding subclonal 
tracking in CLL PDX models. Previous studies have 
demonstrated that cytogenetic evolution in CLL predicts 
for inferior clinical outcome and frequently anticipates 
disease progression [2, 11, 12, 29–31]. However, both 
conventional FISH and targeted sequencing have limited 
value in the assessment of cytogenetic architecture or 
evolutionary dynamics because neither assesses multiple 
genetic aberrations within the same cell.
In this proof of principal study, we exploited the 
ability of multiplexed-FISH, a method that requires only 
a minor amendment of the standard laboratory technique, 
to identify and assess multiple, clinically relevant 
cytogenetic lesions within individual CLL cells. CLL is 
particularly amenable to such an approach due to the low 
number of recurrent cytogenetic aberrations, with only 7 
lesions, namely del(13q), trisomy 12, del(11q), del(17p), 
del(6q), amp(2p) and del(8p), found to be present in more 
than 3% of CLL patients [32]. To demonstrate the utility 
of multiplexed-FISH, we focused on the first 5 of these 
lesions, which are among the most functionally significant 
cytogenetic aberrations in CLL. Del(17p13) results in the 
concomitant loss of TP53 and MIR3676, with the former 
being essential for the DNA damage response, and the 
latter in inhibiting the CLL oncogene, TCL1A. In del(11q), 
the deleted region involves ATM, a DNA repair gene, and 
frequently BIRC3, a gene important for the regulation 
of non-canonical NFKB signaling. The loss of DLEU2 
(MIR15A/16-1 cluster) which occurs with del(13q14) 
results in the enhancement of CLL cell proliferation, 
whereas trisomy 12 is associated with NOTCH1 mutations 
and increased integrin expression [33–36].
Due to the finite number of cytogenetic loci that 
can be assessed, multiplexed-FISH does not provide a 
comprehensive genome-wide catalogue of cytogenetic 
aberrations. Rather, by targeted analysis of a number of 
specific loci, it enables characterization of the relationships 
between functionally important cytogenetic aberrations in 
single CLL cells, from which CLL subpopulations can be 
readily identified. Hence, multiplexed-FISH provides an 
accurate and clinically relevant high resolution snapshot 
of the CLL cytogenetic architecture.
In most CLL studies to date, clonal dynamics have 
been inferred from bulk cellular populations. Here, we 
demonstrate that this can be directly observed at the 
single-cell level. Through analysis of longitudinal samples 
by multiplexed-FISH, we tracked temporal changes 
to the cytogenetic architecture in individual patients 
under different treatments. While in some instances 
no substantive change was observed, in other cases the 
cytogenetic architecture was perturbed by treatment, 
resulting in the selection of specific subpopulations, 
with or without an accompanying emergence of novel 
subpopulations (Figure 3). Due to a lack of sequential 
samples at earlier time-points, we were unable to 
directly examine pre-treatment evolutionary dynamics. 
Nevertheless, using the composition of cytogenetic 
aberrations in individual CLL cells, we were able to 
reconstruct possible evolutionary histories (Figure 2).
We showed that multiplexed-FISH can be readily 
applied to PDX models. Indeed, as we demonstrated in a 
series of proof-of-principle experiments, the application 
of multiplexed-FISH to PDX permits treatment-induced 
clonal changes to be distinguished from those occurring 
as a result of spontaneous clonal progression (Figures 
4 & 5). We consider this to be a potentially important 
application for the pre-clinical evaluation of novel 
therapies. The outgrowth of tumor subpopulations that are 
less affected by treatment can give rise to eventual disease 
relapse. Hence, therapeutic efficacy should be measured 
not only in terms of the overall cytotoxic potential, but 
also of the ability to curtail CLL subpopulations with 
genomically destabilizing aberrations, thereby limiting 
genetic diversification and clonal evolution. In this 
respect, multiplexed-FISH can be used to monitor for 
spontaneous or treatment-induced changes of CLL 
subpopulations containing adverse cytogenetic features 
such as del(17p) or del(11q), as well as the emergence 
of cytogenetic complexity in vivo. This information may 
provide an insight into the likely nature and potential 
durability of treatment responses in patients with specific 
CLL cytogenetic compositions. Given the trend towards 
improved treatment stratification, this pre-clinical tool 
could potentially inform selection of appropriate patients 
into clinical trials.
In our proof-of-principle experiments, 
chemotherapeutic agents such as chlorambucil appeared to 
propel clonal selection, whereas treatment-induced clonal 
changes were not always observed with chemotherapy-
free treatments (Figure 5). Although these results are by no 
means conclusive owing to the small sample size, they are 
however, broadly consistent with observations reported in 
clinical studies [13, 37–39] and confirm the mechanisms 
inferred by NGS [3, 40]. Thus, it remains to be determined 
whether this method allows the robust inference of general 
mechanisms broadly applicable to CLL. Future application 
of these experiments, initiated as part of a pre-clinical drug 
evaluation study, could encompass a more comprehensive 
panel of samples with different cytogenetic features.
There are a number of caveats to the use of PDXs 
and multiplexed-FISH in CLL [41]. Firstly, the level of 
tumor engraftment in CLL PDXs is lower than that of 
acute leukemias, which limits graft duration. Secondly, 
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PDX models provide only a limited reflection of the 
CLL tumor microenvironment, as recipient mice are, 
by necessity, immunodeficient, and the murine stromal 
microenvironment is not identical to that in humans. 
However, we showed that this can be compensated to an 
extent by co-engrafting autologous T-cells, which also has 
the added benefits of improving engraftment efficiency 
and reflecting a facet of patient-related biology wherein 
CLL is also reliant on T-cells. In addition, the limited 
sensitivity of multiplexed-FISH imposes a restriction 
on the ability to distinguish between the appearance of 
novel and pre-existing subclones present below the limit 
of detection. However, it is important to note that the 
multiplexed-FISH results corroborate reported data from 
whole exome sequencing [32], a method with similar 
sensitivity (4%). Furthermore, although multiplexed-
FISH provides a functionally important snapshot of the 
cytogenetic architecture and evolutionary landscape, it 
does not capture the full extent of subclonal dynamics and 
genomic aberrations, such as gene mutations. Therefore, 
future improvements may need to incorporate single-
cell sequencing approaches to address such possibilities. 
Finally, manipulation of engraftment duration and timing 
of analysis for individual CLL cases might provide more 
faithful recapitulation of patient’s clonal architecture and 
thus contribute to more precise assessment of treatment 
effects. Nevertheless, the significance of our study lies 
in the demonstration that treatment-induced clonal 
dynamics can be modeled in vivo, and these can be readily 
distinguished from spontaneous clonal progression, with 
important pre-clinical applicability.
In summary, this is the first report of a strategy 
to model CLL clonal dynamics in vivo that allows 
differentiation between spontaneous and treatment-
induced clonal selection. FISH-based technology is well-
established, validated, widely available, inexpensive 
and reasonably sensitive. Multiplexed-FISH provides a 
clinically relevant snapshot of the cytogenetic architecture 
at single-cell resolution. By applying multiplexed-FISH 
to PDX models, we provide proof-of-principle that they 
can be used to examine the evolutionary dynamics of 
cytogenetic aberrations at the single-cell level under 
different treatments. This can be applied to evaluate 
novel therapies in the pre-clinical setting, and to 
inform treatment choice for CLL patients with different 
cytogenetic composition, including those with adverse 
features or complex karyotype.
MATERIALS AND METHODS
Ethics statement
All studies involving clinical samples were approved 
by the UK National Research Ethics Service Committee 
West Midlands - Solihull and were conducted according 
to institutional guidelines and the principles expressed in 
the Declaration of Helsinki. Informed, written consent was 
obtained from all participants.
Investigations involving animals have been 
conducted in accordance with the ethical standards and 
according to the Declaration of Helsinki and according to 
national; United Kingdom Home Office; and international 
guidelines and have been approved by the UK National 
Research Ethics Service Committee West Midlands - 
Solihull.
Patient samples
Samples were obtained from 128 CLL patients. 
Peripheral blood mononuclear cells (PBMCs) were sorted 
for CLL cells using a B-CLL cell isolation kit (Miltenyi 
Biotec; 130-093-661). Purity of sorted cells was assessed 
by flow cytometry and subsequent FISH analyses were 
corrected for the proportion of CLL cells in each sample 
by subtracting from the percentage of cells identified 
without cytogenetic aberrations.
FISH analysis
FISH analysis was performed according to a 
standard protocol.[42] Whilst standard FISH uses probes 
with internal controls to interrogate individual loci, 
multiplexed-FISH employs bespoke probe combinations 
specific for each sample as previously determined by 
standard FISH. Cultured cell suspensions were harvested 
by treating with hypotonic solution (0.075M KCl; Sigma; 
P9541) for 15 minutes prior to fixation using a 3:1 mix 
of methanol: acetic acid (VWR International; 20847.307: 
Fisher Scientific; A/0360/PB170). Slides were exposed 
to 3.5µl probes; individual for standard FISH and 
simultaneous multiplexed-combinations for multiplexed-
FISH (Supplementary Tables 1 & 2). Hybridizations were 
performed overnight on a HYBrite (Abbott Molecular) 
with an initial denaturation at 73°C for 2 minutes followed 
by incubation at 37°C for 16 hours. Cells were visualized 
on an Olympus BX50 microscope using a 100× objective. 
At least 200 cells were analyzed per patient sample. 
Samples were considered to have deletions of 11q, 
6q, 13q, 17p or trisomy 12 if it was identified in more 
than 6%, 7%, 7.5% 7.5% or 3% of all analyzed cells, 
respectively, as determined by analysis of normal PBMCs. 
The proportion of cells with each deletion was compared 
between standard FISH and multiplexed-FISH and found 
to be similar. Subclones with multiple abnormalities 
were determined to be genuine, and not resulting from 
signal drop-out, if they were observed in ≥4% of a patient 
sample.
Generation of PDX models and treatment 
administration
PDX models were established in 6-12 week old, 
male and female, NOD/Shi-SCID/IL-2Rγctm1sug/Jic (NOG), 
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Mus musculus Linnaeus, 1758 (mouse) strain animals (in-
house) as previously described [43, 44].
Ibrutinib (Seleckchem; S2680) was resuspended 
in 1% methylcellulose and 0.4% Cremephor EL (Sigma; 
M0262 and C5135), and administered daily for 9 days by 
oral gavage at 12.5mg/kg, a dose which is sufficient to 
ensure 90% occupancy of Bruton tyrosine kinase (BTK) 
[45]. Rituximab (40mg/kg; Roche; 2530376), or saline 
control was given intravenously 3 times per week.[46] 
Fludarabine (0.625mg/kg, TEVA; 231-10-04151) and 
cyclophosphamide (6.25mg/kg, Baxter; 1001995501) or 
saline (control) were injected intraperitoneally 3 times per 
week, for two weeks, [47] whereas chlorambucil (5mg/kg; 
Sigma; CO253) or 3% dimethyl sulfoxide (DMSO, Sigma; 
D2650) vehicle control was administered daily for 5 days 
intraperitonally [48].
At specific time points (one week following 
treatment with chlorambucil, fludarabine/
cyclophosphamide or rituximab and the next day 
following treatment with ibrutinib) animals were sacrificed 
and single cell solutions produced from their homogenized 
spleens. CLL cells were sorted by flow-cytometry as 
demonstrated in the Supplementary Figure 1.
Statistical analysis
Statistical analysis was performed using unpaired 
Student’s t-test or two-way ANOVA with Bonferroni 
post hoc comparison, P<0.05 was considered significant. 
Comparison of subclonal architecture of paired or serial 
patient samples was performed using the Chi-squared 
test, P<0.05 was taken to indicate clonal selection. All 
analyses were performed using GraphPad Prism version 
5.0 (GraphPad Software, San Diego, CA).
Abbreviations
ALL, acute lymphoblastic leukemia; amp, 
amplified; ANOVA, analysis of variance; BCR, B-cell 
receptor; BTK, Bruton tyrosine kinase; CLL, chronic 
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fludarabine with chlorambucil; FISH, fluorescent in situ 
hybridization; NGS, next generation sequencing; NOG, 
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xenograft; PFS, progression free survival.
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